Harbin Medisan Pharmaceutical (SHE:002900) obtained approval from China's National Medical Products Administration for the supplemental application of diltiazem hydrochloride for injection after it passed regulatory evaluation, according to a Shenzhen bourse filing on Thursday.
The evaluation tested the consistency in the quality and efficiency of the drug.
The drug is used to treat paroxysmal supraventricular tachycardia, atrial fibrillation, or atrial flutter, as well as abnormal hypertension during surgery and unstable angina.
The company's shares rose over 2% at the close of Thursday's trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments